Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.51 |
| ▸ | ACACB | O00763 | 6/20 | 0.50 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | RET | P07949 | 4/20 | 0.42 |
| ▸ | PARP1 | P09874 | 2/20 | 0.42 |
| ▸ | TNKS | O95271 | 1/20 | 0.42 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.42 |
| ▸ | SPR | P35270 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20468943 | 0.89 | CYP11B2 (0.53) | CYP11B2ACACBSCD5HDAC2HDAC1 | |
| SCHEMBL20468957 | 0.82 | ACACB (0.52) | CYP11B2ACACBSCD5RETSPR | |
| SCHEMBL20468951 | 0.81 | CYP11B2 (0.53) | CYP11B2ACACBSCD5HDAC2HDAC1 | |
| SCHEMBL20468952 | 0.80 | OGA (0.53) | CYP11B2ACACBSCD5HDAC2HDAC1 | |
| SCHEMBL20468945 | 0.79 | ACACB (0.52) | CYP11B2ACACBSCD5HDAC2HDAC1 | |
| SCHEMBL20469058 | 0.79 | CYP11B2 (0.53) | CYP11B2ACACBSCD5HDAC2HDAC1 | |
| SCHEMBL20468950 | 0.79 | ACACB (0.52) | CYP11B2ACACBSCD5HDAC2HDAC1 | |
| SCHEMBL20468940 | 0.78 | CYP11B2 (0.53) | CYP11B2ACACBSCD5HDAC2HDAC1 | |
| SCHEMBL20469072 | 0.78 | CYP11B2 (0.59) | CYP11B2ACACBSCD5HDAC2HDAC1 | |
| SCHEMBL20468941 | 0.78 | CYP11B2 (0.49) | CYP11B2ACACBSCD5HDAC2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200048267-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2020-02-13 | — | — | US | disclosed |
| WO-2018141984-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2018-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048267-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | CYP11B2 4635/4885ACACB 639/4885SCD5 1478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.